Solvonis Therapeutics PLC (SVNS)

ORD GBP0.001

Sell: 0.24p|Buy: 0.26p|Change: 0 (0%)

Open

0.25p

Previous close

0.25p

Trade high

0.26p

Volume

7,394,567

Year high

0.40p

Year low

0.1095p

Dividend yield

–

Market capitalisation

£17.02 mn

P/E ratio

1.25

ISIN

GB00BMD1Z199

This share can be held in a Dealing account Stocks and shares ISA Lifetime ISA JISA SIPPand can be used with Dividend reinvestment

Share price

Performance 12/12/2025

1D | 1M | 3M | 1Y | 3Y ann | 5Y ann | 10Y ann

	Total return (%)
Solvonis Therapeutics PLC	0.00
More...

Company profile

Solvonis Therapeutics PLC, formerly Graft Polymer (UK) PLC focuses on the development of polymer modification and drug delivery systems. It has licensed its Drug Delivery System platform IP to MGC Pharmaceuticals in relation to MGC Pharma's CimetrA product. The group's products address customer needs across a wide range of end-use markets, from automotive through to medical, and are not dependent on one market segment. The Company operates in two business segments being polymer development and production in Slovenia.

Sector

Industrials

News

Recent trades

Date	Time	Price	Quantity	Value (£)
12/12/2025	04:25:29	0.2497	30,000	74.91
12/12/2025	04:23:05	0.249	1,101,326	2,742.30
12/12/2025	03:57:23	0.2499	19,531	48.81
12/12/2025	03:22:47	0.2524	200	0.50
12/12/2025	03:21:31	0.249	369,644	920.41

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.